G
Gert Müller-Berghaus
Researcher at Max Planck Society
Publications - 44
Citations - 3542
Gert Müller-Berghaus is an academic researcher from Max Planck Society. The author has contributed to research in topics: Heparin & Endothelial stem cell. The author has an hindex of 18, co-authored 44 publications receiving 3449 citations.
Papers
More filters
Journal ArticleDOI
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Volker Henn,Joseph R. Slupsky,Michael Gräfe,Ioannis Anagnostopoulos,Reinhold Förster,Gert Müller-Berghaus,Richard A. Kroczek +6 more
TL;DR: In this paper, platelets express CD40L within seconds of activation in vitro and in the process of thrombus formation in vivo, indicating that platelets are not only involved in haemostasis but that they also directly initiate an inflammatory response of the vessel wall.
Journal ArticleDOI
Activated Platelets Induce Tissue Factor Expression on Human Umbilical Vein Endothelial Cells by Ligation of CD40
Joseph R. Slupsky,Matthias Kalbas,Antje Willuweit,Volker Henn,Richard A. Kroczek,Gert Müller-Berghaus +5 more
TL;DR: It is shown that activated platelets induce tissue factor (TF) expression on endothelial cells in a CD40/CD154-dependent manner, and that the magnitude of this response can equal that induced by TNFe.
Journal ArticleDOI
Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
Bernd Pötzsch,Katharina Madlener,Christoph Seelig,Christian F Riess,Andreas Greinacher,Gert Müller-Berghaus +5 more
TL;DR: The whole blood ECT to be a suitable assay for monitoring of r-hirudin anticoagulation in cardiac surgery and the short measuring time with less than 120 seconds warrant the whole blood clotting time (ECT) assay.
Journal ArticleDOI
Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay
TL;DR: The data demonstrate that the ECT is a rapid and easily perfor mable clotting assay which allows accurate measurement of r-hirudin plasma levels and is not influenced by treatment with heparin, aprotinin or oral anticoagulants.
Journal ArticleDOI
Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.
TL;DR: In 1994, shortly after a heat-treated prothrombin complex concentrate (PCC) had been withdrawn from the German market due to transmission of hepatitis B, the license of another brand was withdrawn, due to 3 acute fatalities associated with the use of this product.